Intercalary frozen autografts for reconstruction of bone defects following meta-/diaphyseal tumor resection at the extremities

Jingyan Yang¹, Wenze Li², Rongjie Feng² and Dong Li²*

Abstract

Background  For patients with malignant limb tumors, salvage surgery can be achieved using endoprosthesis or biological reconstructions like allograft or autograft. In carefully selected patients, resected bone can be recycled after sterilization using methods like autoclaving, irradiation, pasteurization or freezing with liquid nitrogen. We evaluated the clinical outcome and complications of malignant limb tumors treated with intercalary resection and frozen autograft reconstruction.

Methods  We reviewed 33 patients whose malignant bone tumors were treated by wide resection and reconstruction with recycling liquid nitrogen-treated autografts between 2006 and 2017. Limb function, bone union at the osteotomy site and complications were evaluated. Functional outcome was assessed using the Musculoskeletal Tumor Society (MSTS) scoring system.

Results  The cohort comprised 16 males and 17 females, with a mean age of 35.4 years (14–76 years). The most common tumor was osteosarcoma (7 cases). Tumors were located in the humerus (5), ulna (1), femur (10) and tibia (17). The mean follow-up was 49.9 months (range 12–127 months). Of the 33 patients, 16 remained disease-free, and 3 were alive with disease. The mean size of the defect after tumor resection was 11.6 cm (range 6–25 cm). Bone union was achieved in 32 patients, with a mean union time of 8.8 months (range 4–18 months). Complications included 1 graft nonunion, 2 infections (1 superficial, 1 deep infection), 1 leg length discrepancy, 2 graft fractures and 3 local recurrences. The mean MSTS score was 87.2% (range 70–100%).

Conclusion  Liquid nitrogen-treated tumor-bearing autograft is an effective option for biological reconstruction after meta-/diaphyseal tumor resection of long bones. This method has excellent clinical outcomes and is especially recommended for patients with no severe osteolytic bone tumors.

Keywords  Biological reconstruction, Limb salvage surgery, Liquid nitrogen, Malignant bone tumor, Recycling autograft
With the application of neoadjuvant chemotherapy and surgical staging, there has been great progress in the treatment of patients with malignant limb tumors [1, 2]. In recent years, limb salvage surgery has become increasingly popular after tumor resection because of its better overall survival rate and functional outcome than amputation [2, 3].

When the tumor is located in the diaphyseal or metaphyseal regions of long bones, intercalary excision is usually performed to remove the tumor and preserve the adjacent joints. The bone defect after tumor resection can be reconstructed with nonbiological (endo-prosthesis) [4] or biological (such as allograft [5], recycling tumor-bearing autograft [6], vascularized [7] or nonvascularized fibular graft [8], distraction osteogenesis [9]) reconstruction.

In recent years, reconstruction with recycling tumor-bearing autografts has become popular because it is adaptable and easily performed and has a very low risk of viral disease transmission [10]. Several methods of recycling have been developed, such as autoclaving [11], irradiation [12] and pasteurization [13]. However, these recycling methods require special equipment or strict thermal control and usually cause bone weakness, resulting in bone absorption and pathological fracture.

In 1999, based on in vitro and in vivo studies of the hypothermic effects of liquid nitrogen on osteosarcoma cells [14], Tsuchiya et al. introduced and clinically applied a reconstruction technique with tumor-bearing autografts treated with liquid nitrogen, and the long-term outcome was satisfactory [6, 15]. This technique has many advantages: simplicity, a perfect fit, a shorter union period, sufficient biomechanical strength, osteoinduction, osteoconduction, ease of soft-tissue attachment, low cost and a low risk of viral disease transmission.

In this study, we reviewed and analyzed the clinical outcome and complications of patients treated with intercalary frozen autografts after resection of malignant limb tumors.

**Methods**

From 2006 to 2017, 40 patients with malignant bone tumors of the limbs underwent intercalary tumor resection and reconstruction with recycled frozen autografts. All patients were selected as following criteria: (1) Lesions were located in the diaphyseal or metaphyseal region of a long bone, and adjacent joints were preserved after tumor resection. (2) Age ≥14 years. (3) Lesions were widely excised with at least 2-cm margin. (4) Postoperative follow-up was at least 12 months, with clinical and radiological assessments performed. Of the 40 patients, 33 were eligible for inclusion in this study (Table 1). Seven cases were excluded from this study owing to younger than 14 years (5 cases) or inadequate resection margin (2 cases).

All diagnoses were confirmed by preoperative biopsy. Patients with osteosarcomas and Ewing’s sarcomas received neoadjuvant chemotherapy. All patients received postoperative chemotherapy, except for those with chondrosarcomas. The length of resection was determined based on preoperative Magnetic Resonance Imaging (MRI).

The intercalary tumor-bearing autografts were treated with free freezing techniques using liquid nitrogen. Briefly, the tumor and a cuff of normal tissue peripheral to the tumor were excised en bloc, with a minimum 2 cm margin. The epiphyseal plate was sacrificed if necessary (in case 13, the tumor was 2-cm away from the epiphysis, transepiphyseal osteotomy was made to achieve wide resection). Intraoperative frozen sections of marrow/bone samples from osteotomy sites were taken to confirm the clean margin. Any attached soft tissues and gross tumors were removed from the resected bone, and the canals were curetted. Then, the bone was soaked in liquid nitrogen for 20 min, thawed at room temperature (~26 °C) for 15 min, and rinsed in distilled water for 15 min. The recycled bone was implanted into the bone defect and fixed by a locking plate (Fig. 1) or intramedullary nail (Fig. 2). Allografts or cement were used to fill bone defects as well as to increase strength after curettage in the recycled bone. Allografts were also performed at the junction sites.

Bone union was assessed with X-ray every month until the grafted bone united. Follow-up radiographs were obtained every 3 months for the first year and then every 6 months to check for recurrences and metastases.

Patients were encouraged to begin range of motion exercises immediately after the surgery. Partial weight bearing was allowed at one month after the operation. Full weight bearing was permitted until solid bone union was achieved. Radiological evidence of bone union in osteotomy sites included obscured osteotomy lines or sufficient bridging callus at the host-graft junction.

We evaluated the reconstruction methods, function of the affected extremities, bone union at the osteotomy site and complications. The functional outcome at the final follow-up was evaluated using the Musculoskeletal Tumor Society (MSTS) scoring system [16].

**Results**

Details on the treatment results are presented in Table 1. The cohort comprised 16 males and 17 females, with a mean age of 35.4 years (14–76 years). The diagnoses were 7 osteosarcomas, 6 metastases, 4 Ewing’s sarcomas, 4 chondrosarcomas, 3 synovial sarcomas, 3 malignant fibrous histiocytomas of bone, 3 malignant peripheral schwannomas, 2 lymphomas, and 1 fibrosarcoma of
| No. | Gender /age (yrs) | Site     | Histology                  | Length (cm) | Fixation | Bony union (months) | MSTS score (%) | Complications (time; treatment) | Follow-up (months) | Outcome |
|-----|------------------|----------|----------------------------|-------------|-----------|---------------------|----------------|---------------------------------|--------------------|---------|
| 1   | F/54             | tibia    | lymphoma                   | 7.5         | nail      | 7                   | 100            | superficial infection (2 weeks po; debridement) | 52                 | AWD     |
| 2   | M/59             | humerus  | Metastasis (lung)          | 6           | plate     | 10                  | 93             |                                  | 45                 | AWD     |
| 3   | F/21             | femur    | osteosarcoma               | 12          | plate     | 8                   | 83             |                                  | 118                | NED     |
| 4   | M/59             | femur    | malignant peripheral schwannoma | 13       | nail      | 6                   | 90             | recurrence (24 months po; resection) | 32                 | DOD     |
| 5   | F/16             | tibia    | osteosarcoma               | 10          | nail      | 12                  | 80             |                                  | 28                 | DOD     |
| 6   | F/17             | femur    | osteosarcoma               | 15          | plate     | 9                   | 83             |                                  | 28                 | DOD     |
| 7   | M/16             | femur    | Ewing's sarcoma            | 8           | plate     | 4                   | 93             |                                  | 54                 | NED     |
| 8   | F/19             | humerus  | malignant peripheral schwannoma | 12.5     | nail      | 6                   | 90             | recurrence (30 months po; amputation) | 44                 | NED     |
| 9   | M/26             | humerus  | chondrosarcoma             | 10          | plate     | 8                   | 86             |                                  | 92                 | NED     |
| 10  | M/19             | tibia    | Ewing's sarcoma            | 11          | nail      | 10                  | 90             |                                  | 36                 | NED     |
| 11  | F/51             | humerus  | chondrosarcoma             | 11.5        | plate     | 10                  | 93             |                                  | 88                 | NED     |
| 12  | F/68             | tibia    | Metastasis (breast)        | 12          | nail      | 12                  | 86             |                                  | 12                 | DOD     |
| 13  | M/14             | tibia    | Ewing's sarcoma            | 8           | plate     | 8                   | 76             | leg shortening, 4 cm (shoe lifts) | 42                 | NED     |
| 14  | F/15             | tibia    | malignant peripheral schwannoma | 10        | plate     | 8                   | 83             |                                  | 60                 | NED     |
| 15  | M/71             | ulna     | Metastasis (kidney)        | 9           | plate     | 10                  | 96             |                                  | 20                 | DOD     |
| 16  | M/22             | femur    | osteosarcoma               | 25          | plate     | 15                  | 80             | fracture (54 months po; prosthesis) | 75                 | NED     |
| 17  | M/70             | femur    | Metastasis (lung)          | 24          | plate     | -                   | 86             | nonunion (17 months po; die of disease) | 17                 | DOD     |
| 18  | F/49             | femur    | Metastasis (multiple Myeloma) | 14.5     | nail      | 8                   | 86             |                                  | 127                | AWD     |
| 19  | F/14             | tibia    | osteosarcoma               | 12          | plate     | 5                   | 96             |                                  | 56                 | NED     |
| 20  | F/32             | tibia    | synovial sarcoma           | 6           | plate     | 6                   | 93             |                                  | 53                 | DOD     |
| 21  | M/55             | femur    | chondrosarcoma             | 15          | nail      | 7                   | 80             | recurrence (36 months po; prosthesis) | 40                 | NED     |
| 22  | F/45             | tibia    | malignant fibrous histiocytoma | 8         | plate     | 6                   | 93             |                                  | 36                 | DOD     |
| 23  | M/16             | femur    | Ewing's sarcoma            | 16          | nail      | 8                   | 90             |                                  | 32                 | DOD     |
| 24  | M/16             | femur    | osteosarcoma               | 18          | nail      | 10                  | 93             |                                  | 50                 | DOD     |
| 25  | M/17             | tibia    | chondrosarcoma             | 7.5         | plate     | 11                  | 86             |                                  | 63                 | NED     |
| 26  | F/22             | tibia    | synovial sarcoma           | 13          | plate     | 18                  | 96             |                                  | 126                | NED     |
| 27  | M/56             | humerus  | malignant fibrous histiocytoma | 11       | nail      | 9                   | 90             |                                  | 30                 | DOD     |
| 28  | M/76             | tibia    | lymphoma                   | 11          | nail      | 8                   | 70             | deep infection (13 months po; amputation) | 33                 | DOD     |
| 29  | F/17             | tibia    | malignant fibrous histiocytoma | 9.5       | plate     | 10                  | 90             |                                  | 48                 | NED     |
| 30  | F/15             | tibia    | osteosarcoma               | 10          | plate     | 10                  | 70             | Fracture (30 months po; internal fixation and allograft) | 32                 | NED     |
Out of 33 cases of tumors, 6 soft tissue sarcomas (3 synovial sarcomas and 3 malignant peripheral schwannomas) invade the bone; the rest tumors originate from the bone. Tumors were located in the humerus (5), ulna (1), femur (10) and tibia (17). This study was approved by the Institutional Ethics Committee of our hospital.

The mean follow-up was 49.9 months (range 12–127 months). At the last follow-up, 16 patients remained disease-free, 3 patients were alive with disease, and 14 patients had died of the disease or metastasis. The mean size of the defect after tumor resection was 11.6 cm (range 6–25 cm). During follow-up, the frozen autografts were removed in four cases (12.1%): two cases due to local recurrence, one due to severe infection and one due to fracture.

Bone union was achieved in 32 patients, with a mean union time of 8.8 months (range 4–18 months). Primary union (<12 months) occurred in 28 of the 33 patients (84.8%), delayed union (≥12 months) in 4 (12.1%), and nonunion in 1 (3.0%). Fixation with intramedullary nailing was performed in 15 patients (45.5%); fixation with plating was carried out in the remaining 18 patients (54.5%).

Nine complications occurred in 9 patients, including 1 graft nonunion, 2 infections (1 superficial, 1 deep infection), 3 local recurrences, 2 graft fractures and 1 leg length discrepancy (LLD).

One 70-year-old male with femoral metastasis of lung cancer developed nonunion and died of the disease uneventfully (case 17). During the survival period, he

| No. | Gender /age(yrs) | Site    | Histology                  | Length (cm) | Fixation | Bony union (months) | MSTS score (%) | Complications (time;treatment) | Follow-up (months) | Outcome |
|-----|------------------|---------|-----------------------------|-------------|-----------|---------------------|----------------|-------------------------------|-------------------|---------|
| 31  | M/31             | tibia   | fibrosarcoma                | 11          | nail      | 6                   | 86             |                                | 14                | NED     |
| 32  | F/34             | femur   | synovial sarcoma            | 10          | nail      | 5                   | 86             |                                | 42                | DOD     |
| 33  | F/55             | tibia   | Metastasis (lung)           | 7           | nail      | 11                  | 83             |                                | 22                | DOD     |

Yrs years, M male, F female, MSTS musculoskeletal tumour society, po postoperation, AWD alive with disease, DOD died of disease, NED no evidence of disease
only had slight limb pain and could walk on canes. No additional revision surgery was performed.

Infections developed in 2 patients with tibial lymphoma (case 1 and 28). In case 1, superficial infection occurred during the early postoperative period and was treated successfully with debridement. Case 28 was a 76-year-old male with severe diabetes; a deep infection occurred at 13 months after surgery and amputation was performed finally.

All three local recurrences occurred in the surrounding soft tissues (case 4, 8 and 21). Case 4 received another wide excision. In case 8, amputation was performed because of severe vascular involvement after recurrence. In case 21, malignant cells recurred very close to the autograft, invading the femur and were managed by wide resection and prosthesis reconstruction; the frozen autograft was removed.

Fractures occurred in two patients (case 16 and 30). One fracture (case 16) occurred owning to graft resorption and was managed by conversion to tumor prosthesis. The other autograft fracture (case 30) was seen at 30 months after surgery because of injury, and was successfully managed with internal fixation and allograft.

Leg length discrepancy (LLD) was seen in one 14-year-old teenager with tibial Ewing’s sarcoma (case 13). It was due to sacrifice of the epiphysis. The affected limb was about 4-cm shorter than the contralateral limb after follow-up of 42 months. He was managed conservatively using shoe lifts.

Functional outcomes were assessed with the MSTS scoring system, with a mean score of 87.2% (range 70–100%). The function of the limb was rated as excellent in 23 patients (69.7%), good in 7 (21.2%), and fair in 3 (9.1%).

**Discussion**

There are several options to achieve reconstruction of intercalary meta-/diaphyseal defects following tumor resection. Segmental prosthesis has been widely used to provide good function with quick recovery; however, prosthesis’ durability becomes an issue over time [17, 18]. It cannot be considered a permanent solution for reconstruction. Distraction osteogenesis may be an alternative limb salvage technique, but it is time-consuming, unsuitable for large defects, and requires surgery many times [9]. Another choice of biological reconstruction is free vascularized or nonvascularized fibula graft; nevertheless, it has complications associated with the donor site; furthermore, the risk of stress fracture may be higher than other biological reconstructions [7, 8]. Many reports are mentioning the use of allograft can be a valuable solution to reconstruct the defect following segmental excision; however, mechanical complications are frequent, especially graft non-union and fracture; therefore,
additional vascularized fibula graft is usually needed to ameliorate final results [5, 19].

Several techniques have been developed to devitalize and recycle the resected bone, including autoclaving, irradiation and pasteurization, but these methods demand strict thermal control and special equipment [11–13]. Furthermore, these techniques have been associated with a high rate of complications. Pan et al. used autoclaved autografts for limb-salvage reconstruction and reported that the rates of nonunion, infection, and fracture were 30%, 20%, and 20%, respectively [20]. Oike et al. reported a 14.8% infection rate and a 33% nonunion rate using extracorporeal irradiated autografts [21]. In a study investigating pasteurized autografts, the rates of deep infection, bone nonunion, and fracture were 15%, 42%, and 23%, respectively [22].

Liquid nitrogen has been used to treat bone tumors for some time. In 1969, Marcove et al. utilized liquid nitrogen for palliative treatment in patients with primary and metastatic bone tumors [23]. Many authors have reported the clinical use of liquid nitrogen as an adjuvant to curettage for benign, aggressive or malignant tumors [24–26]. In 2003, Yamamoto et al. verified the efficacy of exposing tumor cells to liquid nitrogen and found that the treated bone could maintain intact mechanical strength [14]. Tsuchiya et al. reported in 2005 clinical results of reconstruction with tumor-bearing bone treated with liquid nitrogen [6]. Since then, several authors have described the use of frozen autografts for reconstruction after excision of the tumor (Table 2) [6, 15, 27–30].

There have been many studies demonstrating the strong ability of liquid nitrogen treatment to kill tumor cells and the low possibility of local recurrence within recycled tumor-bearing autografts. The main mechanism of cryo sterilization is crystal formation and dehydration of tumor cells, which are more sensitive to low temperatures than normal cells [31, 32]. The process of rapid freezing and slow thawing may cause fatal damage to tumor cells. It was also found that the number of cycles of liquid nitrogen treatment, either one or two, resulted in no significant difference with regard to effects of cell killing [14]. We used one-cycle steps of freezing in liquid nitrogen for 20 min, thawing at room temperature for 15 min and then rinsing in distilled water for 15 min. Only 3 local recurrences (9.1%) occurred in this cohort. The reported recurrence rate was approximately 7.1–11.8% (Table 2) [6, 15, 27–30]. Besides, most authors found recurrences were located in the surrounding soft tissues rather than the recycled bones, which was consistent with our results [6, 15, 29, 30]. Tsuchiya et al. attributed it to insufficient surgical resection [6]. We found that all three recurrences were near the side of the neurovascular sheath, probably owing to local satellite lesions or venous tumor thrombi. Special attention should be focused on the curative wide margin of this area.

The osteoinductive and osteoconductive properties of frozen autografts could be retained [33]. Histological sections showed newly formed bone, osteocytes and microvessels in all portions of the grafted bone removed from patients, and good bone fusion was seen at the host-graft junction [34]. The reported bony union rate was between 83.3% and 100%, with typically 5.2 to 10.2 months to reunion (Table 2) [6, 15, 27–30]. Compared with other reconstruction techniques, the union rates of frozen autografts are comparable with those of vascularized fibular grafts (86-100%) [7, 35], but higher than those of allografts (57-94%) [36–38] and nonvascularized fibular grafts (76-89%) [8, 35, 39]. In our study, bone union was seen in 32 of 33 patients (97.0%), with a mean union period of 8.7 months. Nonunion was seen in only one patient with femoral metastasis. The reported union rates of frozen autografts are also higher than those of other devitalized techniques including irradiated autografts (69-93%) [12, 21], autoclaved autografts (70%) [20],

### Table 2: Demographic data and outcomes of patients treated with frozen autograft in previous studies

| Author       | Published year | Tsuchiya 2005 | Tsuchiya 2010 | Igarashi 2014 | Paholpak 2015 | Zekry 2017 | Garg 2020 |
|--------------|----------------|---------------|---------------|---------------|---------------|------------|------------|
| Cases        | 28             | 33            | 36            | 12            | 34            | 10         |
| (range)      | (10-54)        | (7-69)        | (16-163)      | (12-86)       | (24-214)      | (6-97)     |
| Rate of bony union | 92.9%         | 93.9%         | 83.3%         | 100%          | 97.1%         | 93.8%      |
| Union period (months) Mean | 6.7          | 7.3           | 6.2           | 8.2           | 10.2          | 5.2        |
| (range)      | (2-11)         | (2-11)        | (2-11)        | (3-12)        | (3-36)        | (4-7)      |
| Function (MSTS score) Mean | 71.4% Excellent | 75.7% Excellent | 72.2% Excellent | 79% | 86.8% | 80.2% |
| (range)      | (10.7%Good)    | (15.1%Good)   | (19.4%Good)   | (66.7-93.3%)  | (30-100%)     | (75-85%)   |
| Complications |                |               |               |               |               |            |
| Infection (NO./percentage) | 3/10.7%       | 4/12.1%       | 4/11.1%       | 3/25%         | 2/5.9%        | 0          |
| Recurrence (NO./percentage) | 2/7.1%       | 3/9.1%        | 4/11.1%       | 1/8.3%        | 4/11.8%       | 0          |
| Fracture (NO./percentage) | 2/7.1%       | 2/6.1%        | 6/16.7%       | 0             | 5/14.7%       | 1/10%      |

The osteoinductive and osteoconductive properties of frozen autografts could be retained [33]. Histological sections showed newly formed bone, osteocytes and microvessels in all portions of the grafted bone removed from patients, and good bone fusion was seen at the host-graft junction [34]. The reported bony union rate was between 83.3% and 100%, with typically 5.2 to 10.2 months to reunion (Table 2) [6, 15, 27–30]. Compared with other reconstruction techniques, the union rates of frozen autografts are comparable with those of vascularized fibular grafts (86-100%) [7, 35], but higher than those of allografts (57-94%) [36–38] and nonvascularized fibular grafts (76-89%) [8, 35, 39]. In our study, bone union was seen in 32 of 33 patients (97.0%), with a mean union period of 8.7 months. Nonunion was seen in only one patient with femoral metastasis. The reported union rates of frozen autografts are also higher than those of other devitalized techniques including irradiated autografts (69-93%) [12, 21], autoclaved autografts (70%) [20],
and pasteurized autografts (58-76%) [13, 22]. The high union rate may be attributed to the good preservation of bone morphogenetic activity of the frozen autografts.

As tumor patients survive longer, there are more concerns about autograft fracture. Reported fracture rates of frozen autografts range from 7.1 to 19.4% (Table 2) [6, 15, 27–30], which are lower than those of allografts (7-45%) [36–38], autoclaved bones (8.7-20%) [11, 20] and pasteurized bones (9.5-23%) [13, 22]. The rate of fracture is low because of early bony union and the intact initial strength of the recycled bone. Biomechanical tests have revealed that the initial strength of liquid nitrogen-treated bones is higher than that of autoclaved bones [14]. In addition, bone remodeling and revitalization in frozen bones occurs earlier than that in allograft, autoclaved or pasteurized bone [34]. Fracture thus remains a remote possibility, and only two (6.1%) occurred in our group. Nevertheless, in most patients, bone cortices are usually destroyed by malignant tumors, and the biomechanical strength might decrease depending on the extent of destruction. Therefore, a careful assessment of bone quality is needed before the resected bone is recycled. It is best for mild osteolytic or osteoblastic tumors but not for severe osteolytic lesions.

For frozen autograft reconstruction, there is no clear evidence that the type of fixation is related to the risk of non-union and graft fracture. To date, the selection of fixation type is mainly based on the surgeon’s preference. Intramedullary nail is easy to align correctly at diaphysis but difficult to control cortical displacement at metaphysis. Therefore, we preferred to use intramedullary nail if both osteotomy lines were at the diaphysis, while use plate for reconstruction if the osteotomy was performed through the metaphysis.

In addition to bone nonunion and fracture, other complications, such as infection and limb shortening, have been documented. In the current cohort, infection was seen in two patients (6.1%). The reported infection rates of frozen autografts range 5.9-12.1% [6, 15, 27, 29, 30], which is lower than those of allografts (0–28%) [36–38], irradiated autografts (14.8%) [21], autoclaved autografts (20%) [20] and pasteurized autografts (15%) [22]. Additional surgeries are usually needed to control infection, including debridement and irrigation or removal of the autograft. Garg et al. suggest that vancomycin-mixed normal saline be used to prevent infection during the recycling process [27].

Leg length discrepancy (LLD) is inevitable in adolescent patients, especially when the epiphysis is invaded by the tumor or sacrificed during resection [40]. To address LLD following limb salvage surgery, expandable prostheses have been developed [41]. However, besides the high complication rate, up to 50% of patients do not undergo further lengthening procedures due to oncological failures or overestimation of expected LLD [42]. Vogt et al. thought that the indication and the choice of length equalization method were always elective and decided by the informed patient; LLD between 2 and 5 cm could be equalized by shoe lift and/or insoles [43]. In skeletally immature patients, contralateral epiphysiodesis is an option to treat differences in leg length; but special attention should be paid to the effect of the procedure on body proportion and height [44]. Equalization of LLD of more than 5 cm can be achieved by distraction osteogenesis using external fixators or fully implantable intramedullary nails [45, 46]. In our cohort, the epiphysis of a 14-year-old teenager with tibial Ewing’s sarcoma was excised to achieve a negative margin. The predicted LLD was about 3 cm, and the patient was reluctant to receive contralateral epiphysiodesis. During follow-up of 42 months, the affected limb was about 4 cm shorter than the contralateral limb and was managed conservatively using shoe lifts. Additional limb lengthening may be considered after skeletal maturity.

This study included 6 cases of solitary bone metastasis. Patients with limb metastasis, especially those with severe osteolytic lesions, are usually treated with resection and segmental prosthesis reconstruction [47]. Segmental prosthesis currently gives the best short- and medium-term results for limb-salvage reconstruction in the treatment of bone metastases [20]. However, in developing countries, the cost of tumor prosthesis is beyond the reach of much of the population. Some authors reported the use of frozen tumor-bearing bone as an affordable alternative to the use of prostheses [6, 15, 29, 30]. Nevertheless, the technique should only be used in carefully selected patients with metastasis. We consider that frozen autograft is indicated for those patients if the lesion is solitary, the recycling bone has sufficient biomechanical strength, and good primary oncological control has been achieved.

The MSTS functional score has been reported to be 79–86.8% and “excellent” results were seen in most patients (over 70%) (Table 2) [6, 15, 27–30]. In our group, the mean MSTS score was 87.2%, and “excellent” results were seen in 69.7% of patients (23/33), with a good range of joint motion. The functional results are comparable with those reported in previous studies. With this reconstruction method, adjacent joints could be preserved, and recycled autografts could be easily reattached by soft tissues and muscles, which led to good muscle control and satisfactory functional scoring.

This study has some limitations. First, it is difficult to draw very objective conclusions because of the study’s retrospective nature, small sample size, and lack of a control group. Larger-scale controlled studies should be conducted. Second, this study includes a heterogeneous study sample with different diagnoses, tumor locations,
and fixation methods. All of these factors make it difficult to analyze differences in outcome and complications. More studies are needed to contribute to standardizing this promising technique.

**Conclusion**

Our results suggest that liquid nitrogen-treated tumor-bearing autograft is an effective option for biological reconstruction after meta-/diaphyseal tumor resection at the extremities. Once incorporated, this approach offers a permanent form of reconstruction with excellent clinical outcomes, including high functional scores and a low complication rate. The application of this method is especially recommended for patients with no severe osteolytic bone tumors.

**Abbreviations**

MSTS  Musculoskeletal Tumor Society.
MRI  Magnetic Resonance Imaging.
LLD  Leg length discrepancy.

**Acknowledgements**

Not applicable.

**Author contributions**

Jingyan Yang and Dong Li designed the study and wrote the manuscript. Wenze Li and Rongjie Feng collected and analyzed the data. Wenze Li prepared Figs. 1 and 2. All authors reviewed the manuscript.

**Funding**

This work was supported by the Medical and Health Science and Technology Development Project of Shandong Province, 2017WS092.

**Data Availability**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the Institutional Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong First Medical University. Informed consent was obtained from all patients and/or their legal guardian(s). All methods were carried out in accordance with relevant guidelines and regulations.

**Consent for publication**

Written informed consents were obtained from all subjects and/or their legal guardian(s) for the use of their clinical data.

**Competing interests**

The authors declare that they have no competing interests.

**Received:** 7 March 2022  /  **Accepted:** 14 September 2022

**Published online:** 30 September 2022

**References**

1. Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC, et al. Long-term results (> 25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 2012;118(23):5888–93.
2. Kamal AF, Widyawarman H, Husodo K, Hutagalung EU, Rajabto W. Clinical Outcome and Survival of Osteosarcoma Patients in Cipto Mangunkusumo Hospital: Limb Salvage Surgery versus Amputation. Acta Med Indones. 2016;48(3):175–83.
3. Papakonstantinou E, Stamatopoulos A, I. Athanasiadis D, Kenanidis E, Potoupinis M, Hadicd AB, et al. Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotheraphy: A systematic review and meta-analysis. J Bone Oncol. 2020;25(10):103319.
4. Smolle MA, Andreoud D, Tunn PU, Leitner A. Advances in tumour endoprostheses: a systematic review. EFORT Open Rev. 2019;4(7):445–59.
5. Zucchini R, Staals EL, Fiore M, Campanacci L, Gianinni C, Manfrini M, et al. Intercalary reconstruction of the distal femur with or without physical preservation: results and impact on limb growth. Eur J Orthop Surg Traumatol. 2021.
6. Tsuichiya H, Wan SL, Sakayama K, Yamamoto N, Nishida H, Tomita K. Reconstruction using an autograft containing tumour treated by liquid nitrogen. J Bone Joint Surg Br. 2005;87(2):218–25.
7. Hsu RW, Wood MB, Sim FH, Chao EY. Free vascularised fibular grafting for reconstruction after tumour resection. J Bone Joint Surg Br. 1997;79(1):36–42.
8. Kaewpornsawan K, Eamsobhana P. Free non-vascularized fibular graft for treatment of large bone defect around the elbow in pediatric patients. Eur J Orthop Surg Traumatol. 2017;27(7):895–900.
9. Lesensky J, Prince DE. Distraction osteogenesis reconstruction of large segmental bone defects after primary tumor resection: pitfalls and benefits. Eur J Orthop Surg Traumatol. 2017;27(6):715–27.
10. Li D, Li P, Ma H, Yang J, Zhang W, Sun C, et al. Extraprosthetic segmental excision for osteofibrous dysplasia of tibia with reconstruction by liquid nitrogen-treated recycled autograft. J Orthop Surg. 2019;24(2):342–6.
11. Asada N, Tsuichiya H, Kitaoka K, Mori Y, Tomita K. Massive autocollected allografts and autografts for limb salvage surgery. A 1–8 year follow-up of 23 patients. Acta Orthop Scand. 1997;68(4):392–5.
12. Doutani H, Takenaka S, Hamada K, Imura Y, Kakunaga S, Tamiai H, et al. A long-term follow-up study of extracorporeal irradiated autografts in limb salvage surgery for malignant bone and soft tissue tumors: A minimum follow-up of 10 years after surgery. J Surg Oncol. 2020;121(8):1276–82.
13. Liu T, Ling L, Zhang Q, Liu Y, Guo X. Evaluation of the Efficacy of Pateurized Autograft and Intramedullary Vascularized Fibular Transfer for Osteosarcoma of the Femoral Diaphysis. Orthop Surg. 2019;11(5):826–34.
14. Yamamoto N, Tsuichiya H, Tomita K. Effects of liquid nitrogen treatment on the proliferation of osteosarcoma and the biomechanical properties of normal bone. J Orthop Sci. 2003;8(3):374–80.
15. Igarashi K, Yamamoto N, Shira T, Hayashi K, Nishida H, Kimura H, et al. The long-term outcome following the use of frozen autograft treated with liquid nitrogen in the management of bone and soft-tissue sarcomas. Bone Joint J. 2014;96-B(4):555–61.
16. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993(286):241–6.
17. Benevienia J, Kirchner R, Patterson F, Beebe K, Wirtz DC, Riverso S, et al. Outcomes of a Modular Interiacal Endoprostheses as Treatment for Segmental Defects of the Femur, Tibia, and Humerus. Clin Orthop Relat Res. 2016;474(2):539–48.
18. Hanna SA, Sewell MD, Aston WJ, Pollock RC, Skinner JA, Cannon SR, et al. Femoral diaphyseal endoprosthetic reconstruction after segmental resection of primary bone tumours. J Bone Joint Surg Br. 2010;92(6):867–74.
19. Giannini C, Sambri A, Dalla Rosa M, Zucchini R, Bochicchio V, Fiore M, et al. Intercalary bone graft of the tibia: case series and review of the literature. Eur J Orthop Surg Traumatol. 2020;30(8):1421–7.
20. Pan KL, Chan WH, Ong GB, Premsenth T, Zulkarnain M, Norlida D, et al. Limb salvage in osteosarcoma using autoaclved tumor-bearing bone. World J Surg Oncol. 2012;10:105.
21. Dike N, Kawashima H, Ogose A, Hatano H, Arizumi T, Kaida M, et al. Long-term outcomes of an extracorporeal irradiated autograft for limb salvage operations in musculoskeletal tumours: over ten years’ observation. Bone Joint J. 2019;101-B(9):1151–9.
22. Han I, Kim JH, Cho HS, Kim HS. Low-heat treated autograft versus allograft for intercalary reconstruction of malignant bone tumors. J Surg Oncol. 2014;110(7):823–7.
24. Malawer MM, Bickels J, Meller I, Buch RG, Henshaw RM, Kollender Y. Cryosurgery in the treatment of giant cell tumor. A long-term followup study. Clin Orthop Relat Res. 1999(359):176–88.

25. Malawer MM, Dunham W. Cryosurgery and acrylic cementation as surgical adjuncts in the treatment of aggressive (benign) bone tumors. Analysis of 25 patients below the age of 21. Clin Orthop Relat Res. 1991(262):42–57.

26. Marcove RC, Abou Zahr K, Huvos AG, Ogihara W. Cryosurgery in osteogenic sarcoma: report of three cases. Compr Ther. 1984(10(1):52–60.

27. Garg SK, Aggarwal P, Vrk J, Punia RPS, Dimri K, Jindal R. Limb Salvage Using Liquid Nitrogen-Treated Tumour-Bearing Autograft: A Single Institutional Experience of 10 Patients. Indian J Orthop. 2002;36(4):210–7.

28. Paholpak P, Sirichativape W, Wisanuyotin T, Kosuwan W, Jeeravipoolvarn P. Clinical results of primary malignant musculoskeletal tumor treated by wide resection and recycling autograft reconstruction using liquid nitrogen. Asia Pac J Clin Oncol. 2015;11(2):14–20.

29. Tsuchiya H, Nishida H, Snawat P, Shirai T, Hayashi K, Takeuchi A, et al. Pedicle frozen autograft reconstruction in malignant bone tumors. J Orthop Sci. 2010;15(3):340–9.

30. Zekry KM, Yamamoto N, Hayashi K, Takeuchi A, Abe K, et al. Inter-calary frozen autograft for reconstruction of malignant bone and soft tissue tumors. Int Orthop. 2017;41(7):1481–7.

31. Kimura TK, Nakagawara G. Current status of cryopreservation of pancreatic islets. Low Temp Med. 1996;22:1–6.

32. Goldstein RS, Hess PW. Cryosurgical treatment of cancer. Vet Clin North Am. 1977;71(1):51–64.

33. Takata M, Sugimoto N, Yamamoto N, Shirai T, Hayashi K, Nishida H, et al. Activity of bone morphogenetic protein-7 after treatment at various temperatures: freezing vs. pasteurization vs. allograft. Cytobiology. 2011;63(3):233–9.

34. Tanzawa Y, Tsuchiya H, Shirai T, Hayashi K, Y0 Z, Tomita K. Histological examination of frozen autograft treated by liquid nitrogen removed after implantation. J Orthop Sci. 2009;14(6):761–8.

35. Liu S, Tao S, Tan J, Hu X, Liu H, Li Z. Long-term follow-up of fibular graft for the reconstruction of bone defects. Med (Baltim). 2018;97(40):12605.

36. Ghareshaghi M, Peviani MT, Mazdoomi M, Shoosir HR, Hasani M, Seyf P, et al. Evaluation of Clinical Results and Complications of Structural Allograft Reconstruction after Bone Tumor Surgery. Arch Bone Jt Surg. 2016;4(3):316–42.

37. Liu Q, He H, Duan Z, Zeng H, Yuan Y, Wang Z, et al. Inter-calary Allograft to Reconstruct Large-Segment Diaphysis Defects After Resection of Lower Extremity Malignant Bone Tumor. Cancer Manag Res. 2020;12:4299–308.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.